NASDAQ
No price data available for this timeframe.
Fisher Asset Management LLC lowered its position in Veracyte, Inc. (NASDAQ: VCYT) by 11.0% during the undefined quarter, according to the company in its most recent disclosure with the Securities and ...
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service....
Nanovibronix (NASDAQ: NAOV - Get Free Report) and Veracyte (NASDAQ: VCYT - Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the...
Advantage Alpha Capital Partners LP lessened its position in shares of Veracyte, Inc. (NASDAQ: VCYT) by 27.2% in the second quarter, according to its most recent filing with the SEC. The firm owned 19...
AXQ Capital LP bought a new position in shares of Veracyte, Inc. (NASDAQ: VCYT) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. ...
Veracyte surges 27.5% after Q3 earnings and revenues beat estimates, driven by strong Decipher and Afirma test growth....
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. Wolfe Resea...
Veracyte, Inc. ( VCYT ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Shayla Gorman - Director of Investor Relations Marc Stapley - CEO & Director Rebecca Chambers - Executiv...
Veracyte (VCYT) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.19 per share a year ago....
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the third quarter ended September 30, 2025. “We...